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ABSTRACT 
Objective: The present work was aimed to screen material and processing parameters affecting encapsulation efficiency and drug release from 
microspheres.  
Methods: Oxcarbazepine loaded microspheres were prepared employing multiple emulsion solvent evaporation technique. Ratio of chitosan to 
ethyl cellulose, ratio of drug to polymer, stirring speed, ratio of dichloromethane to methanol, amount of Span 80 and the volume of aqueous phase 
were selected as independent variables in the Plackett and Burman design. The microspheres were characterized for percentage yield, percentage 
encapsulation efficiency, particle size distribution and in vitro drug release.  
Results: The critical material and processing parameters affecting encapsulation efficiency were chitosan to ethyl cellulose ratio, volume of water, 
stirring speed and drug to polymer ratio. Initial burst release was affected by volume of water, temperature, dichloromethane to methanol ratio, 
amount of Span 80 and drug to polymer ratio. FTIR study showed compatibility of the drug with excipients.  
Conclusion: The outcome of the study shall be used to calculate risk priority number (RPN) and for devising suitable control strategies for the 
critical factors at industry. 
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INTRODUCTION 
The dosage forms that can accurately control the drug release rates 
and/or target the drug to specific body site will remain in high 
demand in future. Multiparticulate drug delivery systems 
(microspheres) are develop to modify drug release and for 
improvement of bioavailability. Microspheres can also reduce side 
effects, decrease dosing frequency and improve patient compliance 
[1, 2]. Chitosan is composed of β-(1–4)-2-deoxy-2-amino-D-
glucopyranose units and of β-(1–4)-2-deoxy-2-acetamino-D-
glucopyranose units [3]. Chitosan is obtained by alkaline 
deacetylation of chitin [4]. Chitin is obtained from protective cuticles 
of crustaceans such as crabs, shrimps, prawns, lobsters and cell 
walls of some fungi such as aspergillus and mucor. Chitin is 
composed of β-(1,4)-linked N-acetyl-glucosamine units while 
chitosan comprises of copolymers of glucosamine and N-acetyl-
glucosamine [5].  
Chitosan has been extensively used in pharmaceutical industry for 
the development of modified release formulation because it is 
hydrophilic, nontoxic and biodegradable [6-8]. Presence of free 
amino groups in chitosan leads to quick solubilization in acidic 
media and fast release of drug. The drug release can be minimized 
by chemical cross-linking with aldehydes. The toxicity of aldehyde 
limits its use. Hydrophobic polymers can be used in combination 
with chitosan to modulate drug release.  
Ethyl cellulose (EC) is a water insoluble polymer with excellent 
safety records and global compendial acceptance. It can be used for 
modulating drug release by coating compressed tablets or 
microspheres, for taste masking and even as a binder [9-11].  
Oxcarbazepine, an antiepileptic drug, is used in the treatment of 
partial seizures and generalized tonic-clonic seizures in adults and 
children. Immediate release of oxcarbazepine leads to side effect 
such as dizziness, drowsiness, fatigue, nausea, vomiting, headache, 
sleeping trouble, acne, dry mouth or constipation. Short half life 
(about 2 h) requires frequent administration of dosage form to 
maintain therapeutic level of drug in body [12]. Hence, 
Oxcarbazepine was selected as a model drug to design modified 
release microspheres.  
In the present investigation chitosan and ethyl cellulose were used 
in combination to modify oxcarbazepine release. The concept of 
design of experiment was employed for screening of factors. Plackett 
and Burman design is the best reported method for screening [13]. 
The basic objective of quality by design (QbD) is to develop safe, 
effective and customer friendly dosage form.  
MATERIALS AND METHODS 
Materials 
Oxcarbazepine was obtained as gift sample from Torrent research 
centre, India. Chitosan (degree of deacetylation 85%, intrinsic 
viscosity 400 mPas for 1% solution in 1% aqueous acetic acid at 
20°C) was obtained as gift sample from Fisaris industry, Kochi, India. 
The following chemicals were obtained from commercial suppliers 
and used as received: Ethyl cellulose (EC) (Ethocel 10) was 
purchased from Dow Chemical company, Switzerland; methylene 
chloride was purchased from RFCL, New Delhi, India; Span 80 was 
purchased from Loba Chemie, India; Sodium dodecyl sulfate (SDS) 
and acetic acid were purchased from S.D. fine chemicals, Mumbai, 
India. 
Preparation of microspheres 
Chitosan and ethyl cellulose microspheres were prepared by the 
multiple emulsion solvent evaporation technique [14]. Chitosan 
solution was prepared by dissolving chitosan in dilute acetic acid 
solution (2% v/v). Oxcarbazepine was dispersed in chitosan 
solution. Ethyl cellulose was dissolved in methylene chloride or 
mixture of methanol and methylene chloride containing Span 80. 
Chitosan solution containing drug was added drop by drop to the 
ethyl cellulose solution with continuous stirring on a magnetic 
stirrer.  
The primary emulsion was then added to water phase and stirred 
continuously till organic solvent was evaporated. The microspheres 
were filtered and dried. Batches were prepared by using seven 
factors according to design layout shown in Table 1. Levels of factors 
were selected based on preliminary trials. Each batch was prepared 
in duplicate. 
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Table 1: Experimental design for various batches 
Formulation X X1 X2 X3 X4 X5 X6 7 
P1 0.50 01:03 1200 01:00 400 0.5 30 
P2 0.25 01:03 1200 01:01 200 1 30 
P3 0.25 01:01 1200 01:01 400 0.5 40 
P4 0.50 01:01 500 01:01 400 1 30 
P5 0.25 01:03 500 01:00 400 1 40 
P6 0.50 01:01 1200 01:00 200 1 40 
P7 0.50 01:03 500 01:01 200 0.5 40 
P8 0.25 01:01 500 01:00 200 0.5 30 
X1: Chitosan to ethyl cellulose ratio (%), X2: Drug to polymer ratio, X3: Stirring speed (rpm), X4: Dichloromethane to methanol ratio, X5: Volume of 
water (ml), X6: Amount of Span 80 (%), X7
 
: Temperature (°C) 
Evaluation of microspheres 
Drug excipients compatibility studies: 
Fourier transform infrared spectroscopy (FTIR) (FTIR 8400S, 
Simadzu) spectra of drug, polymer, physical mixture of drug and 
polymer were captured. Discs consisting of 2 mg of the sample and 
100 mg of potassium bromide (KBr) were prepared. Spectra were 
scanned between 3900 and 450 cm-1
Percentage yield 
.  
The yield was calculated by dividing the measured weight of 
microspheres by the total weight of all non-volatile components. The % 
yield of microspheres was calculated using following formula [15]: 
 (1) 
Percentage encapsulation efficiency 
The drugs loaded microspheres (15 mg) were dissolved in the 
methanol. The solution was filtered through Whatman filter paper. 
The samples were appropriately diluted and analysed by UV 
spectroscopic (UV-1700, Simadzu) method at a wavelength of 254 
nm [16]. The encapsulation efficiency was calculated from the 
following formula:  
 (2) 
In vitro drug release study 
Oxcarbazepine release from the microspheres was carried out as per 
the US FDA method using USP type II (Paddle type) dissolution 
apparatus. Hypromellose capsule containing microspheres, 
equivalent to 150 mg oxcarbazepine, was added with sinkers in 900 
ml 0.3% sodium dodecyl sulphate (SDS) solution. The dissolution 
medium was stirred at 60 rpm and was maintained at 37±0.5°C. Samples 
were withdrawn periodically and same volume was replaced with fresh 
dissolution medium. The samples were filtered and analysed using UV 
spectroscopic method at a wave length of 256 nm[17].  
Size analysis and morphology  
The formations of microspheres were monitored during preparation 
steps by an optical microscope with transmitted light at 40 X 
magnification. The mean particle size of microspheres was 
calculated by measuring size of hundred particles with the help of a 
calibrated ocular micrometer [18]. The shape and surface 
morphologies of the selected batch microspheres was examined 
using scanning electron microscope (SEM). SEM images of the 
microspheres were recorded using a Philips FE1 scanning electron 
microscope at the required magnification.  
RESULTS 
Multiparticulate sustained release system offers advantages like no 
dose dumping, minimal potential side effect and low inter person 
variability. Chitosan, a positively charged biodegradable polymer, 
was used to formulate oxcarbazepine microspheres. Chitosan 
microspheres showed rapid drug release in acidic dissolution 
medium. To retard the drug release, ethyl cellulose coated chitosan 
microspheres were prepared according to method described by the 
researchers [19]. The encapsulation efficiency was decreased when 
an effort was made to coat the chitosan microspheres with ethyl 
cellulose. The reason for this occurrence could be formation of few 
blank ethyl cellulose microspheres during the process. To address 
this problem, chitosan ethyl cellulose complex microspheres were 
prepared by selecting multiple emulsion solvent evaporation 
technique [14]. Preliminary trials showed that the aggregates were 
formed. Efforts were made to stabilize primary emulsion because it 
has been reported that stability of emulsion affects the morphology 
and porosity of microspheres and there by affect encapsulation and 
drug release [20]. Drug encapsulation and release properties were 
affected by various other factors like drug to polymer ratio, amount 
of external phase and internal phase, amount of surfactant, 
temperature, stirring speed and type of organic solvent [21-24]. 
Seven factors were selected for screening i.e. chitosan to ethyl 
cellulose ratio, drug to polymer ratio, stirring speed, 
dichloromethane to methanol ratio, amount of Span 80 and volume 
of water phase. The design layout is shown in Table 1. The levels of 
these factors were decided by preliminary trials or from literature 
survey. Percentage encapsulation efficiency and burst release were 
selected as dependent variable. 
Drug excipients compatibility studies 
FTIR of oxcarbazepine (Figure 1) shows that drug is in crystalline 
form and the characteristic peaks of drug are shown at 3469.70 cm-1 
and 3342.41 cm-1 .  The physical mixture of chitosan and drug showed 
similar peaks while physical mixture of ethyl cellulose and drug 
showed 3469.70 cm-1 peak was slightly sifted to 3467.77 cm-1
Percentage yield 
.  
The % yield was varied from 70.00 to 93.40%. For all the 
investigated factors the p value > 0.05.  
Influence of investigated parameters on % encapsulation 
efficiency (Y1
Encapsulation efficiency varied from 75.00% to 99.90%. The result 
shown in Table 2 and Figure 2 depicts that significant factors affecting 
encapsulation efficiency were chitosan to ethyl cellulose ratio (X
) 
1), 
volume of water (X5), stirring speed (X3) and drug to polymer ratio (X2
Influence of investigated parameters on burst release (Y
). 
2
The in vitro release of oxcarbazepine in 0.3% SDS (Figure 3) showed 
biphasic release pattern, i.e. initial burst release followed by slow 
release. The burst effect was probably due to quick release of drug 
present on the surface of microspheres. The result shown in Table 2 and 
Figure4 depicts that significant factors affecting burst release were 
volume of water (X
) 
5), temperature (X7), dichloromethane to methanol 
ratio (X4), amount of Span 80 (X6) and drug to polymer ratio (X2
DISCUSSION 
). 
Drug excipients compatibility studies 
Stability of formulation based on selection and quality of raw 
material hence it is advisable to check drug excipient compatibility. 
From the result of FTIR we can conclude that there is no interaction 
between drug and polymers.  
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Any process can be economic to be used for industrial scale 
production only if yield is high. The p value > 0.05 shows that the % 
yield was not significantly affected by investigated factors.  
Influence of investigated parameters on % encapsulation 
efficiency (Y1
It is worth while to note that design of experiment is an important 
element of QbD. In order to identify critical material attributes 
(CMA) and critical process parameters (CPP), multiple regression 
analysis was carried out. A linear model describing the relationship 
between the independent variables and % encapsulation efficiency 
was evaluated. 
) 
Y1 = 89.03-6.32X1-4.20X2- 5.08X3 + 0.77X4 + 5.30X5 + 0.23X6 - 1.08X7 
The effect plot for encapsulation efficiency (Figure2) shows the 
impact of evaluating factors on encapsulation efficiency. Positive 
value for a coefficient indicates that the independent variable 
favours the response and a negative value indicates an inverse 




The probable reason for decrease in encapsulation efficiency is 
dissolution enhancement of oxcarbazepine in water phase. The 
volume of water (X
) showed negative effect on % encapsulation 
efficiency. It is worth while to note that chitosan enhances the 
dissolution of oxcarbazepine [26].  
5
 
) has positive effect on drug encapsulation 
efficiency. 
 
Fig. 1: FTIR of chitosan, ethyl cellulose, pure drug and physical mixture of drug and chitosan and physical mixture of drug and ethyl 
cellulose 
 
Table 2: Statistical analysis of encapsulation efficiency (Y1) and burst release (Y2
Factor 
) 
Encapsulation efficiency (Y1 Burst effect (Y) 2) 
 Coefficient p- value Coefficient p- value 
Chitosan to Ethyl cellulose ratio (X1 -6.3166 ) 0.0005 0.7987 0.4986 
Drug to Polymer ratio (X2 -4.1953 ) 0.0061 -2.7362 0.0413 
Stirring speed (X3 -5.0803 ) 0.0021 -1.4675 0.2291 
Dichloromethane to Methanol ratio (X4 0.7703 ) 0.517 -3.1812 0.0224 
Volume of water (X5 5.3034 ) 0.0016 -5.1125 0.0019 
Amount of Span 80 (X6 0.2253 ) 0.8478 -3.0575 0.0265 
Temperature (X7 -1.0784 ) 0.3704 3.6188 0.0124 
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Fig. 2: Term effect plot for % encapsulation efficiency 
A:A= Chitosan to ethyl cellulose ratio, B:B= Drug to polymer ratio, C:C= Strring speed, D:D= Dichloromethane to methanol ratio, E:E= Volume of 
water, F:F= Amount of Span 80, G:G= Temperature 
 
 
Fig. 3: Mean percentage oxcarbazepine release (n=3) 
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Fig. 4: Term effect plot for burst release at 0.5 h 
A:A= Chitosan to ethyl cellulose ratio, B:B= Drug to polymer ratio, C:C= Strring speed, D:D= Dichloromethane to methanol ratio, E:E= Volume of 
water, F:F= Amount of Span 80, G:G= Temperature 
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Size analysis and morphology:  
Figure 5 shows the particle size distribution of the eight batches of 
microspheres. Microspheres were poly dispersed. Particle size 
ranged from 13.3 to 159.6 μm. The p value for all the independent 
variable is >0.05. SEM study of microspheres is shown in Figure 6. 
 
 
Fig. 5: Particle size distribution of oxcarbazepine microspheres 
 
 
Fig. 6: Scanning electron micrographs of microspheres (batch P6) 
 
This may be due to quick solidification of polymer, which prevents 
diffusion of drug to the external phase. Stirring speed (X3) has 
negative effect on encapsulation efficiency. As the stirring speed 
increases, the mean particle size of microspheres decreases which 
leads to increases in surface area. The final impact is increased drug 
diffusion in continuous phase during microspheres preparation. It is 
reported that factors favouring the increase of mean size could 
increase encapsulation efficiency due to a reduced surface area [27]. 
The drug to polymer ratio (X2) has negative effect on encapsulation 
efficiency. It may be due to increase in chitosan amount as the 
polymer increase. From the result it was found that the 
dichloromethane to methanol ratio (X4), amount of Span 80 (X6) and 
temperature (X7
Influence of investigated parameters on burst release (Y
) had no significant effect (p > 0.05) on % 
encapsulation efficiency of microspheres. 
2
A linear model describing the relationship between the independent 
variable and burst drug release at 0.5 h was evolved. 
) 
Y2= 39.65+0.80X1-2.74X2-1.47X3-3.18X4-5.11X5-3.06X6+ 3.62X7
The effect plot for burst release (Figure4) shows the impact of 
evaluating factors on burst release. The significant factors (*p value 
< 0.05**) affecting burst release were volume of water (X
 (4) 
5), 
temperature (X7), dichloromethane to methanol ratio (X4), amount 
of Span 80 (X6) and drug to polymer ratio (X2) (Table 2). The 
volume of water used in preparation of microspheres has negative 
effect on burst release. Quick diffusion of organic solvent in the outer 
phase and rapid solidification results in decreased burst release. 
Rapid evaporation of solvent at higher temperature may results in 
increased porosity of microspheres and hence quick drug release. 
Due to the formation of stable primary emulsion in presence of 
methanol, the drug might be well entrapped in the microspheres and 
burst drug release was retarded. Also, miscibility of methanol in 
external phase leads to fast solidification of polymer. Span 80 as a 
surfactant increases primary emulsion stability and therefore the 
effect is similar to previous factor. From the result it was found that 
the chitosan to ethyl cellulose ratio (X1) and stirring speed (X3
Size analysis and morphology 
) had 
no significant effect (p value > 0.05) on burst release from 
microspheres. 
The p value for all the independent variable showed that no factor 
had significant effect on size of microspheres. SEM study of 
microspheres (Figure 6) show that microspheres were spherical 
with smooth surface. 
CONCLUSION 
Oxcarbazepine loaded chitosan and ethyl cellulose microspheres, 
prepared without using cross-linking agent, showed acceptable 
physical properties and bi-phasic drug release. The use of design of 
experiment is demonstrated to meet the primary requirements of 
quality by design (QbD). The study indicates the use of Placket and 
Burman Design to identify the important variables for further 
optimization. The volume of water and temperature were selected 
as most important factors affecting the formulation of 
Oxcarbazepine microspheres. Further optimization can be done 
using factorial, box behnkem or central composite design. 
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